News

July 22, 2014 — Boston Scientific announced it received U.S. Food and Drug Administration (FDA) approval for the Rebel platinum chromium coronary stent system, the company's latest-generation bare...

Boston Scientific Rebel Platinum Chromium Coronary Stent System Bare Metal

Boston Scientific Corp. received CE marking for the Rebel Platinum Chromium Coronary Stent System, the company's latest generation ...

tryton stent, bifurcation stenting

clinical trial designed to measure the effectiveness of using a dedicated side branch-covering bare metal...

Biosensors BioMatrix

The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents, percutaneous transluminal coronary angioplasty (PTCA) and cutting balloon catheters....

December 27, 2012 — Biotronik announced that the first implant has taken place in the BIOHELIX-I trial in the United States. The BIOHELIX–I trial is set to evaluate the safety and...

Tryton Side Branch Stent TRYTON Pivotal FDA IDE trial

Tryton Medical Inc. announced the completion of enrollment in the TRYTON Pivotal U.S. Food and Drug Administration (FDA) IDE trial evaluating the Tryton Side Branch...

Svelte Acrobat Bare Metal Stents Svelte Medical Systems Inc

November 9, 2012 — Svelte Medical Systems announced it received conditional approval from the U.S. Food and Drug Administration (FDA) to begin a pivotal study for the Svelte coronary stent...

November 1, 2012 — InspireMD Inc. announced that its proprietary MGuard embolic protection stent (EPS) was shown to be significantly superior when compared to standard bare metal and drug-eluting...

October 3, 2012 — Stentys, a medical technology company commercializing the world's first and only self-apposing stent to...

May 4, 2012 - The U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the Medinol Ltd. Presillion plus cobalt chromium (CoCr) coronary...

Boston Scientific announced its support of the HORIZONS II AMI clinical trial, which is designed to evaluate the safety and efficacy of the Promus Element Plus everolimus-eluting platinum chromium...

February 6, 2012 — A medical technology company commercializing the world's first and only self-apposing stent to treat acute myocardial infarction (AMI), announced today that the APPOSITION III...

November 15, 2011 – A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting...

November 4, 2011 — Medtronic Inc. announced approval by the U.S. Food and Drug Administration (FDA) of the Assurant Cobalt Iliac Balloon-Expandable Stent System.

November 1, 2011 – Boston Scientific released the schedule of its major events and product-related clinical research for the Cardiovascular Research Foundation's (CRF) 23rd annual Transcatheter...

October 25, 2011 — Stentys S.A. announced the publication of the results of the APPOSITION I clinical study in the September issue of the medical journal EuroIntervention.

October 7, 2011 — Boston Scientific Corp. has started patient enrollment in the Omega clinical trial, designed to evaluate the company's Omega platinum chromium bare-metal coronary stent system....

August 31, 2011 — Results of a recent randomized controlled study show the drug-eluting stent Xience V performs well in patients having primary percutaneous coronary intervention (PCI) for ST...

August 17, 2011 — OrbusNeich announced its Genous stent showed no significant difference in target vessel failure (TVF) rate at two years from the Taxus Liberte paclitaxel-eluting stent in...